Here, we use data from the MAximising Therapeutic Utility for Rheumatoid Arthritis (MATURA) consortium (Barton & Pitzalis, 2017) and focus on predicting the change in C‐reactive protein score (CRP), in 28 swollen joint count score (SJC28) and in erythrocyte sedimentation rate (ESR)—three markers of treatment response—using genome‐wide SNP data in RA patients receiving two different treatments: anti‐TNF and MTX. This evidence concerns the gene CRP and rheumatoid arthritis.